JP2007526219A - トランスフェクション薬剤 - Google Patents

トランスフェクション薬剤 Download PDF

Info

Publication number
JP2007526219A
JP2007526219A JP2006515161A JP2006515161A JP2007526219A JP 2007526219 A JP2007526219 A JP 2007526219A JP 2006515161 A JP2006515161 A JP 2006515161A JP 2006515161 A JP2006515161 A JP 2006515161A JP 2007526219 A JP2007526219 A JP 2007526219A
Authority
JP
Japan
Prior art keywords
interferon
group
composition
gene
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006515161A
Other languages
English (en)
Japanese (ja)
Inventor
ジョセフ マコーリフ，
ロバート コナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/455,215 external-priority patent/US20040014709A1/en
Application filed by Canji Inc filed Critical Canji Inc
Priority claimed from PCT/US2004/017612 external-priority patent/WO2004108898A2/en
Publication of JP2007526219A publication Critical patent/JP2007526219A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006515161A 2003-06-04 2004-06-04 トランスフェクション薬剤 Pending JP2007526219A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47592603P 2003-06-04 2003-06-04
US10/455,215 US20040014709A1 (en) 1996-01-08 2003-06-04 Methods and compositions for interferon therapy
PCT/US2004/017788 WO2004108088A2 (en) 2003-06-04 2004-06-04 Methods and compositions for interferon therapy
PCT/US2004/017612 WO2004108898A2 (en) 2003-06-04 2004-06-04 Transfection agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007144212A Division JP2007262081A (ja) 2003-06-04 2007-05-30 トランスフェクション薬剤

Publications (1)

Publication Number Publication Date
JP2007526219A true JP2007526219A (ja) 2007-09-13

Family

ID=33513856

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006515161A Pending JP2007526219A (ja) 2003-06-04 2004-06-04 トランスフェクション薬剤
JP2006515206A Withdrawn JP2006526661A (ja) 2003-06-04 2004-06-04 インターフェロン治療のための方法および組成物
JP2007147517A Pending JP2007269808A (ja) 2003-06-04 2007-06-01 インターフェロン治療のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006515206A Withdrawn JP2006526661A (ja) 2003-06-04 2004-06-04 インターフェロン治療のための方法および組成物
JP2007147517A Pending JP2007269808A (ja) 2003-06-04 2007-06-01 インターフェロン治療のための方法および組成物

Country Status (9)

Country Link
US (1) US20050025742A1 (https=)
EP (2) EP1629085A2 (https=)
JP (3) JP2007526219A (https=)
KR (1) KR20060012661A (https=)
AU (2) AU2004245995A1 (https=)
BR (1) BRPI0410915A (https=)
CA (2) CA2528136A1 (https=)
NO (1) NO20060019L (https=)
WO (1) WO2004108088A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519120A (ja) * 2020-03-19 2023-05-10 トライゼル リミテッド 温度応答型ウイルス貯蔵システム

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
ES2745068T3 (es) * 2001-12-20 2020-02-27 Merck Sharp & Dohme Composiciones de SYN3 y métodos
US20030198624A1 (en) * 2002-03-02 2003-10-23 Mohapatra Shyam S. Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer
CA2484251C (en) 2002-04-30 2015-06-23 University Of South Florida Materials and methods for inhibition of respiratory syncytial virus infection
US7595303B1 (en) * 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
WO2004074314A2 (en) * 2003-02-14 2004-09-02 University Of South Florida Chistosan-microparticles for ifn gene delivery
US7355056B2 (en) * 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
CA2548100C (en) * 2003-12-10 2015-03-24 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
WO2005105136A1 (en) * 2004-04-27 2005-11-10 University Of South Florida Nanogene therapy for cell proliferation disorders
TWI305230B (en) * 2004-06-25 2009-01-11 Univ Feng Chia Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein
CA2590943C (en) 2004-12-13 2013-10-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
EP3442588A4 (en) 2016-04-14 2020-02-19 Trizell Ltd. STABILIZING VIRUS VECTORS
WO2026077967A1 (en) * 2024-10-08 2026-04-16 Ferring International Center Sa Method for making syn3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029186A1 (en) * 1994-04-20 1995-11-02 The Trustees Of Princeton University Compositions and methods for cell transformation
WO1996010038A1 (en) * 1994-09-28 1996-04-04 Apollon, Inc. Multifunctional molecular complexes for gene transfer to cells
WO1999002191A1 (en) * 1997-07-08 1999-01-21 Canji, Inc. Compositions and methods for enhancing delivery of therapeutic agents to cells
US20020111502A1 (en) * 1996-01-08 2002-08-15 Canji, Inc. Compositions and methods for enhancing delivery of therapeutic agents to cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5298222A (en) * 1989-08-09 1994-03-29 Osteotech, Inc. Process for disinfecting musculoskeletal tissue and tissues prepared thereby
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5118512A (en) * 1990-01-23 1992-06-02 Osteotech, Inc. (A Delaware Corp.) Process for cryopreserving biological materials and materials prepared thereby
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029186A1 (en) * 1994-04-20 1995-11-02 The Trustees Of Princeton University Compositions and methods for cell transformation
WO1996010038A1 (en) * 1994-09-28 1996-04-04 Apollon, Inc. Multifunctional molecular complexes for gene transfer to cells
US20020111502A1 (en) * 1996-01-08 2002-08-15 Canji, Inc. Compositions and methods for enhancing delivery of therapeutic agents to cells
WO1999002191A1 (en) * 1997-07-08 1999-01-21 Canji, Inc. Compositions and methods for enhancing delivery of therapeutic agents to cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519120A (ja) * 2020-03-19 2023-05-10 トライゼル リミテッド 温度応答型ウイルス貯蔵システム

Also Published As

Publication number Publication date
BRPI0410915A (pt) 2006-06-27
AU2004245074A1 (en) 2004-12-16
WO2004108088A2 (en) 2004-12-16
EP1628624A2 (en) 2006-03-01
CA2527658A1 (en) 2004-12-16
EP1629085A2 (en) 2006-03-01
NO20060019L (no) 2006-03-03
WO2004108088A3 (en) 2006-04-20
JP2007269808A (ja) 2007-10-18
JP2006526661A (ja) 2006-11-24
KR20060012661A (ko) 2006-02-08
CA2528136A1 (en) 2004-12-16
AU2004245995A1 (en) 2004-12-16
US20050025742A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
US20080234221A1 (en) Transfection agents
JP2007526219A (ja) トランスフェクション薬剤
JP3806445B2 (ja) 治療方法
US8022044B2 (en) Compositions and methods for therapeutic use
EP1987845A2 (en) Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
JP2006526661A5 (https=)
US7534769B2 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
JP2007262081A (ja) トランスフェクション薬剤
JP4727923B2 (ja) Ｓｙｎ３組成物およびその方法
EP1442750A1 (en) Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
JP3806446B2 (ja) 宿主抗腫瘍防御機構刺激
MXPA05012978A (es) Agentes de transfeccion
HK1092813A (en) Transfection agents
HK1028961B (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
TW201249874A (en) An interferon conjugate modified by PEG

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110208